실시간 바이오 인텔리전스 · ADC · CGT

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

8,428+프로그램
40+FDA 승인
3,743+모집 중
ADC 1032·Antibody 4683·CGT 2713차세대 추천 →·Data Tier →
8428프로그램40FDA 승인
206오늘 방문
5,332누적 방문
7303갱신 대기S–CData TierS/A/B차세대→Insight1032HER2 breast4683Antibody2713CGT→Psoriasis→NSCLC40FDA 승인
피드Data Tier차세대Insight

추천 비교

비교 도구 →
HER2 ADCEnhertu · Kadcyla · RC48CD19 CAR-TYescarta · KymriahPD-1Keytruda · Opdivo다발골수종Darzalex · BlenrepTROP2 ADCTrodelvy · Dato-DXd · SGNectin-4 · TROP2Padcev · Trodelvy건선 IL pathwayStelara · Cosentyx · SkyriziAnti-VEGF (안과)Eylea · LucentisAnti-TNFHumira · EnbrelIL-12/23Stelara · Skyrizi아토피·IL-13Dupixent · EbglyssPCSK9 · LDLRepatha · Praluent · LeqvioGLP-1 · incretinSemaglutide · Tirzepatide혈우병 유전자치료Hemgenix · Roctavian겸상적혈구 CGTCasgevy · Lyfgenia망막·DMD 유전자치료Luxturna · Elevidys

빠른 검색 · 이슈 태그

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
다음 갱신 D-7 · 마지막 7월 21일
CGTBiologicstaleAbbVievedotin (RC48) with the est…Phase 2

Granulocyte Colony-Stimulating Factor (Granulocyte Colony-Stimulating Factor)

AML, Childhood; Aml · AML, Childhood

#AMLChildhood#CGT#Phase2#세포유전치료#CAR-T+5
효능 ORR 20.4%임상시험 32상태 RECRUITING
CGTBiologicRui Therapeutics Co., LtdPhase 1

anti-CD19 CAR-NK cells (anti-CD19 CAR-NK cells)

Refractory/Recurrent Central Nervous System Lymphoma · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+5
효능 ORR 0%임상시험 32상태 ACTIVE
CGTBiologicstaleShanghai Unicar-Therapy Bio-med…vedotin (BV), a CD30-direct…Phase 1

CD30+ CAR T-cells (CD30+ CAR T-cells)

Relapsed or Refractory Lymphoma · CD30

#CD30#CGT#Phase1#세포유전치료#CAR-T+5
임상시험 32상태 RECRUITING
CGTBiologicstaleHe HuangPhase 1

CAR-T cells chimeric antigen receptor T cells (CAR-T cells chimeric antigen receptor T cells)

Relapsed/Refractory Acute Myeloid Leukemia(AML) · FRα

#FR#CGT#Phase1#세포유전치료#CAR-T+5
효능 0%임상시험 32상태 RECRUITING
CGTBiologicstaleLiaoning Medical Diagnosis and …designPhase 2

Autologous immune Cells (Autologous immune Cells)

Lung Cancer (Locally Advanced or Metastatic); Liver Cancer (Locally Advanced or Metastatic) · Lung Cancer (Locally Advanced or Metasta

#LungCancerLocallyAdvancedorMetas#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 31상태 RECRUITING
CGTBiologicstaleSyndax Pharmaceuticalscalicheamicin linked to ant…Phase 3

Midostaurin (Midostaurin)

Acute Myeloid Leukemia; Myelodysplastic Syndrome · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#CGT#Phase3#세포유전치료#CAR-T+5
효능 ORR 59.6%임상시험 31상태 RECRUITING
AntibodystaleRocheVedotin in Relapsed/Refract…Phase 2

Glofitamab/Obinutuzumab (Glofitamab/Obinutuzumab)

Richter Syndrome · FRα

#FR#Antibody#Phase2#항체#면역항체+5
효능 ORR 35.3%임상시험 31상태 RECRUITING
AntibodystaleRocheVedotin Plus an Anti-CD20 M…Phase 2

Zanubrutinib and Rituximab (Zanubrutinib and Rituximab)

Untreated Mantle Cell Lymphoma · Mantle Cell Lymphoma

#MantleCellLymphoma#Antibody#Phase2#항체#면역항체+5
효능 ORR 48.7%임상시험 31상태 RECRUITING
AntibodystaleAnaveon AGVedotin ± Pe…Phase 2

KEYTRUDA® (ANV600 + pembrolizumab, ANV600 + pembrolizumab (KEYTRUDA®))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#항체#면역항체+4
효능 ORR 71.4%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 3

atezolizumab (Tecentriq, Tiragolumab and Atezolizumab)

Head and Neck Neoplasms; MSI-H Cancer · Cancer

#Cancer#Antibody#Phase3#항체#면역항체+5
효능 ORR 77.3%임상시험 31상태 RECRUITING
AntibodystaleMerck Sharp & Dohme LLCPhase 3

H2 receptor antagonist (H2 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+4
임상시험 31상태 RECRUITING
AntibodystaleMerck Sharp & Dohme LLCADCsPhase 3

H1 receptor antagonist (H1 receptor antagonist)

Ovarian Cancer; Fallopian Tube Cancer · Lung Neoplasm Malignant

#LungNeoplasmMalignant#Antibody#Phase3#항체#면역항체+5
효능 ORR 6%임상시험 31상태 RECRUITING
AntibodystaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab - 21 Day Cycle)

Endometrial Cancer · Endometrial Cancer

#EndometrialCancer#Antibody#Phase2#항체#면역항체+3
효능 ORR 46.4%임상시험 31상태 RECRUITING
AntibodystaleETOP IBCSG Partners Foundationderuxtecan (Arm 4), followe…Phase 3

durvalumab (Imfinzi, Adjuvant durvalumab)

Non Small Cell Lung Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase3#항체#면역항체+4
효능 ORR 45%임상시험 31상태 RECRUITING
ADCBiologicstaleBeOne MedicinesPhase 1

Anticancer Agents (Anticancer Agents)

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 0%임상시험 31상태 RECRUITING
CGTBiologicstaleVinmec Research Institute of St…Phase 1

Autologous CD19-Targeted CAR-T Cells (Autologous CD19-Targeted CAR-T Cells)

Refractory Systemic Lupus Erythematosus · CD19

#CD19#CGT#Phase1#세포유전치료#CAR-T+4
효능 ORR 92%임상시험 31상태 RECRUITING
AntibodyBiologicstaleKyverna TherapeuticssPhase 2

Anti-CD20 mAB (Anti-CD20 mAB)

Multiple Sclerosis, Primary Progressive; Multiple Sclerosis, Secondary Progressive · CD20

#CD20#Antibody#Phase2#항체#면역항체+5
효능 ORR 89%임상시험 31상태 RECRUITING
CGTBiologicstaleInstitute of Hematology & Blood…Phase 2

Autologous hematopoietic stem cell infusion (Autologous hematopoietic stem cell infusion)

Prolonged Cytopenia Following CAR-T Therapy · Prolonged Cytopenia Following CAR-T Ther

#ProlongedCytopeniaFollowingCAR-T#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 73.33%임상시험 31상태 RECRUITING
ADCBiologicstalePfizerPhase 3

Mylotarg (Gemtuzumab Ozogamicin, Gemtuzumab Ozogamicin (Mylotarg))

Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 0%임상시험 30상태 ACTIVE
ADCBiologicstaleImmunoGen, Inc.Phase 3

Liposome-encapsulated Daunorubicin-Cytarabine (Liposome-encapsulated Daunorubicin-Cytarabine)

Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Recurrent Acute Myeloid Leukemia · Acute Myeloid Leukemia

#AcuteMyeloidLeukemia#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 22%임상시험 30상태 RECRUITING
ADCBiologicstaleHoffmann-La RochePhase 3

Vinflunine (Vinflunine)

Bladder Cancer · Ureteral Cancer

#UreteralCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 46.9%임상시험 30상태 ACTIVE
CGTBiologicstaleKara Yakhteh Tajhiz Azma CompanyPhase 2

anti-CD19 CAR T cell therapy (anti-CD19 CAR T cell therapy)

Relapse/Refractory B-cell Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4
효능 ORR 94%임상시험 30상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 1

Methotrexate/Vinblastine/Doxorubicin/Cisplatin (Methotrexate/Vinblastine/Doxorubicin/Cisplatin)

Muscle Invasive Bladder Urothelial Carcinoma · Muscle Invasive Bladder Urothelial Carci

#MuscleInvasiveBladderUrothelialC#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 9%임상시험 30상태 ACTIVE
ADCBiologicstaleAmgenPreclinical

Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine (Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine)

Anti-CD30; Brentuximab · CD30

#CD30#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 86%임상시험 30상태 ACTIVE
CGTBiologicstaleHrain Biotechnology Co., Ltd.Preclinical

anti-CD19-CAR vector-transduced T cells (anti-CD19-CAR vector-transduced T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD19

#CD19#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 32%임상시험 30상태 ACTIVE

24 / 142 페이지

← 이전다음 →
전체 8,428개 프로그램 보기